Clinical trial
A Study of Mitomycin C, Irinotecan, and Cetuximab
NCT00271011 · University of Michigan Rogel Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00271011 |
|---|---|
| Title | A Study of Mitomycin C, Irinotecan, and Cetuximab |
| Official title | A Phase II Study of Mitomycin C, Irinotecan and Cetuximab in Patients With Previously Treated, Metastatic Colorectal Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Mitomycin C, Cetuximab, Irinotecan. |
| Enrollment | 13 |
| Start date | Dec 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2009 |
| First posted | Dec 29, 2005 |
| Last update posted | Dec 3, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: